

HYPERFINE

Corporate presentation

Hyperfine + Liminal + HealthCor Catalio

July 2021

© 2021 Hyperfine, Inc.



Disclaimer

This presentation is for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to the proposed business combination (“Business Combination”) by and among HealthCor Catalio Acquisition Corp. (“HealthCor Catalio” or the “Company”), Hyperfine, Inc. (“Hyperfine”) and Liminal Sciences, Inc. (“Liminal”). The information contained herein does not purport to be all-inclusive and none of HealthCor Catalio, Hyperfine or Liminal, or any of their respective affiliates, or any of their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this presentation. It is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. You should not construe the contents of this presentation as investment, legal, business or tax advice. You should consult with your own counsel, financial advisor and tax advisor as to legal, business, financial, tax and related matters concerning the matters described herein.

Important Information about the Business Combination and Where to Find It

In connection with the Business Combination, the Company intends to file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “Registration Statement”), which will include a preliminary proxy statement/prospectus and a definitive proxy statement/prospectus, and certain other related documents, which will be both the proxy statement to be distributed to holders of the Company’s ordinary shares in connection with the Company’s solicitation of proxies for the vote by the Company’s shareholders with respect to the Business Combination and other matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities of the Company to be issued in the Business Combination. **The Company’s shareholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus included in the Registration Statement and the amendments thereto and the definitive proxy statement/prospectus, as well as other documents filed with the SEC in connection with the Business Combination, as these materials will contain important information about the parties to the Business Combination Agreement (the “Business Combination Agreement”), the Company and the Business Combination.** After the Registration Statement is declared effective, the definitive proxy statement/prospectus and other relevant materials for the Business Combination will be mailed to shareholders of the Company as of a record date to be established for voting on the Business Combination and other matters as may be described in the Registration Statement. Shareholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s web site at www.sec.gov. In addition, the documents filed by HealthCor Catalio may be obtained free of charge from HealthCor Catalio’s website at www.hccspac.com or by written request to HealthCor Catalio at ir@hccspac.com.

Participants in the Solicitation

The Company and its directors and executive officers may be deemed participants in the solicitation of proxies from the Company’s shareholders with respect to the Business Combination. You can find information about the Company’s directors and executive officers and their ownership of the Company’s securities in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which was filed with the SEC on March 29, 2021, and is available free of charge at the SEC’s web site at www.sec.gov. Additional information regarding the interests of such participants will be contained in the Registration Statement when available.

Hyperfine, Liminal and their respective directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of the Company in connection with the Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the Business Combination will be contained in the Registration Statement when available.

Disclaimer (cont.)

Forward-Looking Statements

This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company’s, Hyperfine’s and Liminal’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s, Hyperfine’s and Liminal’s expectations with respect to future performance, development and commercialization of products and services, potential regulatory approvals, and anticipated financial impacts and other effects of the Business Combination, and the size and potential growth of current or future markets for, and the potential benefits of, Hyperfine’s, Liminal’s and the combined company’s products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside the Company’s, Hyperfine’s and Liminal’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the ability of the Company, Hyperfine and Liminal to meet the closing conditions in the Business Combination Agreement, including due to failure to obtain approval of the shareholders of the Company, Hyperfine and Liminal or certain regulatory approvals, or failure to satisfy other conditions to closing in the Business Combination Agreement; (2) the occurrence of any event, change or other circumstances, including the outcome of any legal proceedings that may be instituted against the Company, Hyperfine or Liminal following the announcement of the Business Combination Agreement and the transactions contemplated therein, that could give rise to the termination of the Business Combination Agreement or could otherwise cause the transactions contemplated therein to fail to close; (3) the inability to obtain or maintain the listing of the combined company’s Class A common stock on the Nasdaq Capital Market, as applicable, following the Business Combination; (4) the risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination; (5) the inability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition and the ability of the combined company to grow and manage growth profitably and retain its key employees; (6) costs related to the Business Combination; (7) changes in applicable laws or regulations; (8) the inability of the combined company to raise financing in the future; (9) the success, cost and timing of Hyperfine’s, Liminal’s and the combined company’s product development activities; (10) the inability of Hyperfine, Liminal or the combined company to obtain and maintain regulatory clearance or approval for their products, and any related restrictions and limitations of any cleared or approved product; (11) the inability of Hyperfine, Liminal or the combined company to identify, in-license or acquire additional technology; (12) the inability of Hyperfine, Liminal or the combined company to maintain Hyperfine’s or Liminal’s existing or future license, manufacturing, supply and distribution agreements; (13) the inability of Hyperfine, Liminal or the combined company to compete with other companies currently marketing or engaged in the development of products and services that Hyperfine or Liminal is currently marketing or developing; (14) the size and growth potential of the markets for Hyperfine’s, Liminal’s and the combined company’s products and services, and each of their ability to serve those markets, either alone or in partnership with others; (15) the pricing of Hyperfine’s, Liminal’s and the combined company’s products and services and reimbursement for medical procedures conducted using Hyperfine’s, Liminal’s and the combined company’s products and services; (16) Hyperfine’s, Liminal’s and the combined company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; (17) Hyperfine’s, Liminal’s and the combined company’s financial performance; (18) the impact of COVID-19 on Hyperfine’s and Liminal’s businesses and/or the ability of the parties to complete the Business Combination; and (19) other risks and uncertainties indicated from time to time in the proxy statement/prospectus relating to the Business Combination, including those under “Risk Factors” in the Registration Statement, and in the Company’s other filings with the SEC.

The Company, Hyperfine and Liminal caution that the foregoing list of factors is not exclusive. The Company, Hyperfine and Liminal caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company, Hyperfine and Liminal do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based.

No Offer or Solicitation

This presentation shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Business Combination. This presentation shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Industry and Market Data

This presentation includes information and statistics regarding market participants in the sectors in which Hyperfine or Liminal compete and other industry data which was obtained from third-party sources, including reports by market research firms and company filings. None of the information provided by the third-party sources has been independently verified. This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners.

Intellectual Property

This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners and are incorporated for illustrative purposes only. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM, C or R symbols. The Company, Hyperfine and Liminal do not intend the use or display of the trademarks, service marks, trade names or copyrights of such other companies herein to imply a relationship with, or endorsement or sponsorship of the Company, Hyperfine or Liminal by, these other companies.

Seasoned management team with history driving platform and application usage



Jonathan Rothberg

Dr. Rothberg is the founder and chairman of each 4Catalyzer company, which have together raised over \$2B across eight-life science and medical device companies. Jonathan's mission is to build technologies that save lives and maximize societal impact.




Chris Gaulin

Chris is a Portfolio Manager of HealthCor. He was a health care Portfolio Manager at Soros Fund Management, health care Sector Lead at Maverick Capital, and Senior Analyst at JP Morgan.



Scott Huennekens

Scott is a successful executive, entrepreneur, board member and investor in medical devices having been the startup CEO of two "unicorns" and a part of 10+ startups or growth companies with market valuations that have totaled over \$6B.



Dave Scott

Dave is a seasoned executive, entrepreneur and was the COO for Verb Surgical. He has more than 25 years of experience building and leading high-performing teams at start-ups and Fortune 500 companies related to surgical robotics, medical imaging and diagnostics.



HealthCor Catalio Acquisition Corp (Nasdaq: HCAQ)



- HealthCor (\$3 billion AUM) founded in 2005 by Joseph Healey and Arthur Cohen
- Partners all have 20+ years investing experience across numerous healthcare cycles
- 10 person investment team with an average of 12 years of investing in the healthcare sector
- Extensive Medtech product experience driving large percentage of historical attribution



- Completed \$207 million SPAC IPO in January 2021. Deal 9x over-subscribed without warrant coverage
- Experienced SPAC BoD: Mike Weinstein, Taylor Harris, Kenan Turnacioglu and Dr. Chris Wolfgang
- Catalio founded by G. Petrocheilos and J. Vogelstein. GP consists of world-renowned scientist-entrepreneurs as well as Coatue Management, Duquesne & Alan Howard



Joseph Healey

HealthCor Founder and SPAC Chairman

Founding partner and Portfolio Manager at HealthCor with 25+ year investing experience. Prior PM at Kingdon Capital



Chris Gaulin

HealthCor Partner and SPAC CEO

Partner and Portfolio Manager at HealthCor with 20+ year investing experience. Prior PM at Soros Fund Management and Maverick Capital



Charlie Nettleton

HealthCor Senior Analyst

Medical Technology Sector Head at HealthCor with ~15 years investing experience. Prior Healthcare banker at JPMorgan

Highly compelling investment characteristics

Large Market Poised for Disruption

Massive TAM of over \$23 billion for imaging with potential to take market share and expand the market category. Both companies could unlock huge markets individually but combined have the potential to build an ecosystem across the care continuum.

Recurring Revenue Business Model

Designed to be a recurring revenue business with annual recurring revenue of greater than \$250MM projected by 2025

Massive Pipeline Opportunity

Product and applications pipeline has the potential to unlock markets with \$50 billion in incremental addressable markets for sensing and guided intervention. Liminal Sciences has the potential to substantially change the way neuro care is delivered by providing non-invasive, real-time brain vitals to doctors that were previously inaccessible.

Hyperfine Capitalized to Succeed

~\$375MM¹ of cash to drive Hyperfine through its investment phase and to positive cash flow

Attractive Valuation Relative to Growth

10.7x 2023E revenues with projected revenue CAGR of 238% 2021 - 2025 versus comparables² at ~13 - 18x 2023E revenues with meaningfully slower growth CAGRs of ~30%+

Transaction overview

Sources, uses and pro forma ownership

Sources of Funds (\$M)

Cash in Trust ¹	\$207.0
Target Shareholders Equity Rollover	\$564.8
Private Placement	\$126.1
Target Cash ²	\$66.0
Sponsor Founder Shares	\$57.9
Total Sources	\$1,021.8


Pro Forma Valuation (\$M)⁵

Illustrative Share Price	\$10.00
Fully Diluted Shares Outstanding (M) ⁴	95.6
Equity Value	\$956.0
+ Debt	\$0.0 ⁶
- Cash	\$374.7
Enterprise Value	\$581.3
2023 Revenue	\$54.2
2023 Revenue Multiple	10.7x

Uses of Funds (\$M)



Equity Issued to Target Shareholders	\$564.8
Cash to Balance Sheet ³	\$374.7
Estimated Transaction Costs	\$24.2
Sponsor Founder Shares	\$57.9
Payment of Loan Payable	\$0.2
Total Uses	\$1,021.8

Pro Forma Valuation⁵



Valuation benchmarking

Merger price set at a discount to similar high growth and disruptive companies to incentivize current and new stakeholders to maximize impact

		Median EV/ Revenue 2023E	Revenue CAGR 2021-2023E
High Growth Med-Tech		12.7x	37.9%
Disruptive Technologies		17.9x	33.7%
HYPERFINE		10.7x	384.4%



Hyperfine Opportunity



HYPERFINE



The best way to predict the future is to make it"

Jonathan M. Rothberg
Vice Chairman and Founder

Our mission:

To provide affordable and accessible imaging, sensing, and guided robotic intervention to revolutionize healthcare for people around the world.

Hyperfine is the third company to go public from the 4C family

HYPERFINE



The Hyperfine ecosystem

Democratizing Imaging, Sensing and Guided Intervention to cover the care continuum


Image
(FDA cleared)



Sense
(in development)



Intervene
(in development)



A full ecosystem solution: Hardware, software, consumables and applications powered by artificial intelligence

Hyperfine has created the next generation of MRI



MRI 1.0
1980



MRI 2.0
1990



MRI 3.0
FDA Cleared 2020

Hyperfine has created the next generation of MRI

MRI 3.0 - FDA Cleared 2020

Patent protected noise cancellation system enables clinical-grade images



Portable low-field MRI



FDA Cleared 2020



Reimbursed under existing imaging codes




Current installed base of 46 units

Current primary clinical uses:

- Stroke
- Hydrocephalus
- Cerebral Trauma
- Acute Mental Status Change



Estimated \$70+ billion opportunity across the ecosystem





Adverse events occur in
22-46%
of cases
during transport

Numerous challenges with traditional MRI today

High cost limits accessibility



Complex site requirements and upgrades



Scheduling delays lead to longer length of stay



Consumption of valuable personnel resources



Risk of adverse events during transportation




Maintaining connection to life support equipment



Workflow benefits



Traditional MRI workflow (25.8 hours)



Hyperfine workflow (90mins, 94% reduction in total workflow time)



Hyperfine addresses challenges of traditional MRI by bringing MRI to the patient



Emergency Department



Intensive Care Units
and Operating Rooms



Global Health

Safer and easier to use resulting in a faster time to diagnosis and treatment

Hyperfine portable MRI clinical use cases with current platform (V1)

Intensive Care Unit

- Acute Mental Status Change
- Ataxia
- Cerebral Edema
- Cerebrovascular Disease
- Cranial Neuropathy
- Extra Ventricular Drain Placement
- Follow-up Intracranial Hemorrhage
- Follow-up Ischemic Stroke
- Follow-up Hematoma
- Stroke
- Tumor Pre- and Post-Op



Rehabilitation Clinic

- Acute Mental Status Change
- Brain Injury After Fall
- Stroke Recovery



Emergency Department

- Blurred Vision
- Cranial Neuropathy
- Dizziness
- Headache
- Numbness
- Stroke
- Tingling
- Traumatic Brain Injury
- Vertigo
- Weakness




Outpatient

- Atrophy Monitoring
- Hydrocephalus (Shunt Check)
- Multiple Sclerosis



Pediatric

- Brain Volumetrics
- Hypoxic Ischemic Encephalopathy
- Hydrocephalus (Dx and Monitoring)
- Sports Injury
- Suspected Abuse



Hyperfine provides compelling platform for stroke diagnosis

15 million people worldwide suffer a stroke annually



MRI scans are better at **detecting ischemic stroke damage** compared to CT scans



Stroke is the **2nd leading cause of death** globally



MRI use for stroke has been limited due to **lack of access** to this expensive equipment and experienced neuroradiologists to interpret the results.



87% strokes are ischemic strokes



Hyperfine offers an affordable MRI platform that can perform diffusion imaging


for stroke diagnosis at the patient's bedside, images can be shared securely with neuroradiologists around the world



Stroke diagnosis confirmed

62 year old male

Presented with new left sided weakness and tremor



Clinical validation of Hyperfine

“Game changer is a good way to put it [...] being able to do the level of sophisticated imaging in an ICU that MRI can provide.”

Dr. Fady Charbel, MD, FAANS, FACS



“Hyperfine provides me with an opportunity to acquire the information, to interpret the information, and to make a decision based on the information that’s in front of me.”

Dr. Shahid Nimjee, MD, PhD, FAANS, FAHA



“Portable MRI should be used to image any patients in ICUs in any [clinical] setting.”

Dr. Michael Schulder, MD, FAANS



Over 25 conference presentations and publications discussing clinical benefits for


Stroke | Hydrocephalus | Hematoma | Multiple sclerosis | Tumor resection

JAMA Neurology | Original Investigation


Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients

Kevin N. Sheth, MD; Mercy H. Mazurek, BS; Matthew M. Yuen, BA; Bradley A. Cahn, BS; Jill T. Shah, BA; Adrienne Ward, RN; Jennifer A. Kim, MD, PhD; Emily J. Gilmore, MD; Guido J. Falcone, MD, ScD, MPH; Nils Petersen, MD, PhD; Kevin T. Gobeske, MD, PhD, MPH; Firas Kaddouh, MD; David Y. Hwang, MD; Joseph Schindler, MD; Lauren Sansing, MD, MS; Charles Matouk, MD; Jonathan Rothberg, PhD; Gordon Sze, MD; Jonathan Siner, MD; Matthew S. Rosen, PhD; Serena Spudich, MD, MA; W. Taylor Kimberly, MD, PhD

C Large left middle cerebral artery



D Right anterior cerebral artery and middle cerebral artery watershed infarctions



Hyperfine business model allows for potential widespread adoption

Subscription Model

\$7,250/month

Over \$261,000 - 3 year contract value

Potential robust recurring revenue stream

Software as a Service model could drive significant gross margin

Subscription service includes:

4 contrast sequences (T1, T2, FLAIR, DWI with accompanying ADC map)

Unlimited service and maintenance

Unlimited user training

Hyperfine Cloud PACS with unlimited Cloud archive


Direct delivery to customer

Estimated Hyperfine economic benefits

Financial Benefits analysis based on data from Large Academic Medical Center

Cost	Amount Saved
ED Length of stay and costs	\$115,000
Hospital LOS and Costs	\$49,000
Transport risks and costs	\$120,000
Annual Total Cost Savings	\$284,000
Annual Hyperfine Cost	\$65,000
Net Annual Cost Savings	\$219,000
Incremental MRI revenue	\$57,000
Net Annual Savings+Revenue	\$276,000





Pipeline Opportunity



Innovative R&D engine designed to expand product roadmap

Potential benefits:



Improved usability



Expanded Addressable Market



Lower cost of goods



Automated Stroke Detection



Liminal will democratize brain sensing

Heart monitors are easy, accurate, and universal

After an accident



Before and during surgery



At a checkup



While exercising



...but access to brain monitors is restricted.

Liminal non-invasive brain vital sensor

Breakthrough AEG Technology designed to unlock access to blood flow and pressure



Non-Invasive

Risk-free use on every patient to enable broader access and earlier diagnosis



Continuous Trend Analysis


Continuous sensing to build trends for data-backed treatment



Easy to use

Designed to be easy to use for immediate, precise care

Brain-sensing clinical opportunities



Hyperfine's goal is to build an ecosystem across the care continuum

Powered by artificial intelligence

Hyperfine aims to provide affordable care at the patient's side...


Precision when and where it matters



Sense



Image



Intervene

Future product roadmap

To expand from imaging to guided intervention

2023

Guided Intervention



V2 MRI

Imaging neuro, c-spine, extremities and interventional procedures



Brain Sensing

Non-invasively monitor brain vitals for blood flow and pressure



Guided Intervention

Image-guided interventions with real-time registration for surgical navigation



Guided Robotics

MRI-guided robotics to improve accuracy for life saving interventions



Breast MRI

Breast screenings as a safer alternative to detect cancer




Financial Overview


Install base growth has potential to drive strong revenue and margin profile

5-year revenue projection


\$ in millions




Gross Margin



Imaging install base



Sensing install base



Investment priorities

Imaging

Clinical and regulatory

Commercialization globally

Next generation and consumables product development

Execute deep learning AI apps

Sensing

Regulatory and clinical trial execution

Commercialization in US and Global

Product development

Guided Intervention

Interventional MRI, robotics, and consumables development

Highly compelling investment characteristics

Large Market Poised for Disruption

Massive TAM of over \$23 billion for imaging with potential to take market share and expand the market category. Both companies could unlock huge markets individually but combined have the potential to build an ecosystem across the care continuum.

Recurring Revenue Business Model

Designed to be a recurring revenue business with annual recurring revenue of greater than \$250MM projected by 2025

Massive Pipeline Opportunity

Product and applications pipeline has the potential to unlock markets with \$50 billion in incremental addressable markets for sensing and guided intervention. Liminal Sciences has the potential to substantially change the way neuro care is delivered by providing non-invasive, real-time brain vitals to doctors that were previously inaccessible.

Hyperfine Capitalized to Succeed

~\$375MM¹ of cash to drive Hyperfine through its investment phase and to positive cash flow

Attractive Valuation Relative to Growth

10.7x 2023E revenues with projected revenue CAGR of 238% 2021 - 2025 versus comparables² at ~13 - 18x 2023E revenues with meaningfully slower growth CAGRs of ~30%+

HYPERFINE

Thank you

Come join us!
Help us make the future.

July 2021

© 2021 Hyperfine, Inc.



Proven team, clear mission, driven to succeed



Dave Scott

Chief Executive Officer



Dr. Khan Siddiqui

Chief Strategy Officer
& Chief Medical Officer



Mark Hughes

Chief Operations Officer



Chris Ward

Head of Marketing



Neela Paykel

General Counsel



Robert Glashow

Acting Chief Financial
Officer



Ruby Gill

Head of Product



Rob Korn

SVP Global Sales



Dr. Eddie Knopp

Sr. Medical Director



Kamyar Firouzi

Chief Technology Officer,
Liminal



Ryan Silvestri

Head of Product
Engineering



Dr. David Rosenthal

Chief Medical Officer,
4Catalyzer



Brian Welch

Sr. Director Clinical Science



Michael Poole

Head of Advanced
Development



Elena Kaye

Senior Scientist /
Interventional Leader

99 issued patents and 285 pending applications

Operates on the same amount of power as a coffee maker
<1.6kW powered MRI system

<50" diameter self-contained MRI system

Noise cancelling technology to reduce interference

MRI scanner on wheels



Competitive imaging

	Portable CT CereTom	Portable MRI Swoop
Setting	ED - Neuro ICU	ED - Neuro ICU
Imaging	CT, CTA, CTP	T1, T2, FLAIR, DWI
Use Cases	Stroke	Stroke
Limitations	Larger size - Ionizing radiation	Ergonomics
Benefits	Widely available and fast	Reduces radiation exposure

	Medtronic	GE	Philips	Siemens	Hitachi	Fonar	IMRIS
Product Name	<ul style="list-style-type: none"> - Polestar N10 0.12T (Odin) - Polestar N20 (Odin) - Polestar N30 (Odin) 	Signa 0.5 T	<ul style="list-style-type: none"> - Panorama 1T - Panorama 0.23T 	MAGNETOM Open 0.2T	AIRIS 0.3T	Fonar 360°	<ul style="list-style-type: none"> - Siemens - MAGNETOM 1.5T - MAGNETOM 3T
Overview	Does not require extensive renovation of the OR or restrictions of instruments	Only 15 systems built, discontinued due to complicated siting requirements	Open MRI for obese and claustrophobic patients	It can be disassembled into 3 pieces for installation w/out site construction	Accommodates obese, claustrophobia, and pediatric patients	Dual-purpose: when it's not used for surgery, it can be used, as is, for Dx.	Ceiling-mounted scanner can move in/out of OR
Use cases	Tumor resections with real-time imaging.	<ul style="list-style-type: none"> - Minimally invasive procedures - Focused ultrasound of breast lesions - Biopsies 	<ul style="list-style-type: none"> - Thermal ablation of brain tumors - Biopsy procedures and kinematic joint studies 	Tumor resections	Minimally invasive pain therapy: spinal disc prolapses, back and neck pain or arthritis, puncture of haematomas	Minimally invasive therapies: RF, chemotherapy, microwave, drugs	<ul style="list-style-type: none"> - DBS positioning - Drug-delivery - Tumor resection - Laser ablation
Features	Image fusion of pre-operative diagnostic scans (CT, MR, PET and fMRI) with intra-operative images	<ul style="list-style-type: none"> - Integrated focused ultrasound into scanner table setup - 3D tracking system 	Optional OptoGuide enables real-time needle tracking	"instant field off" function to shut off the magnetic field within seconds if there is a complication		Special moveable bed allows the patient to be positioned at any height and any angle	<ul style="list-style-type: none"> - BrainLab Brain Suite SW nav partnership - Ceiling mounted to move between OR's
Notes	Total anesthesia and operation times are prolonged	Concept promoted before RSNA '93, unclear if commercialized	Eliminates \$30k craniotomy; reduce hospital stay and patient morbidity	Priced below most states certificate of need limits	Laser	Revenues from diagnostic scanning can subsidize surgical program	<ul style="list-style-type: none"> - Can be used for diagnostic imaging - "iMRI to the patient"
Availability	<ul style="list-style-type: none"> - No longer sold - N10: \$960,000 	<ul style="list-style-type: none"> - No longer sold - Signa: up to \$2M 	No longer sold	<ul style="list-style-type: none"> - \$900,000 - UCLA: Dr. R. Lufkin 	No longer sold	Work in progress	<ul style="list-style-type: none"> - \$1.5+ M - 75 systems WW